1Pool PE. The case for metabolic hypertension : Is it time to restructure the hypertension paradigm? Prog Cardiovasc DIs 1993;36:1.
2Imura O. Insulin resistance and hypertension in Japanese.Hypertens Res 1996;19(Suppl 1):s1.
3Hypertension in Diabetes Study Group. Increased risk of cardiovascular complications in hypertensive type 2 diabetes patients.J Hypertens 1993,11:319-325.
4Hansson L, Zanchetti A, Garruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment(HOT) randomised trial. Lancet 1998 ; 351 : 1755-1762.
5Heart Outcoms Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 2000; 355 : 253- 259.
6Turner R, Homen R, Stratton I, et al. Efficacy of atenolol and captopril in reducing risk of maerovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317 :703- 720.
7Turner R, Homen R, Stratton I, et al. Efficacy of atenolol and captopril in redueing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703- 720.
8Das SK,Sanyal K,Basu A.Study of urban community survey in India:growing trend of high prevalence of hypertension in a developing country[J].Int J Med Sci,2005,2(2):70-78.
